Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2017, Article ID 6167345, 5 pages
https://doi.org/10.1155/2017/6167345
Case Report

Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a Case

1Hematology Division, IRCCS Ca’ Granda-Maggiore Policlinico Hospital Foundation and University of Milan, Milan, Italy
2Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “L. and A. Seragnoli,” University of Bologna, Bologna, Italy

Correspondence should be addressed to Alessandra Iurlo; ti.im.ocinilcilop@olruia

Received 11 April 2017; Revised 19 June 2017; Accepted 12 July 2017; Published 14 August 2017

Academic Editor: Stephen Langabeer

Copyright © 2017 Cristina Bucelli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Kantarjian, S. O'Brien, E. Jabbour et al., “Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience,” Blood, vol. 119, no. 9, pp. 1981–1987, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Saußele, L. Kalmanti, M. Lauseker et al., “Management and outcome of CML-blast crisis: results from the randomized CML study IV,” Haematologica, p. P275, 2014. View at Google Scholar
  3. D. Lindoerfer, V. S. Hoffmann, G. Rosti et al., “The EUTOS population-based registry: evaluation of baseline characteristics and first treatment choices of 3045 newly diagnosed chronic myeloid leukemia (CML) patients from 20 European countries,” Haematologica, p. S680, 2014. View at Google Scholar
  4. E. J. Jabbour, T. P. Hughes, J. E. Cortés, H. M. Kantarjian, and A. Hochhaus, “Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia,” Leukemia and Lymphoma, vol. 55, no. 7, pp. 1451–1462, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Hehlmann, “How I treat CML blast crisis,” Blood, vol. 120, no. 4, pp. 737–747, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Hehlmann and S. Saussele, “Treatment of chronic myeloid leukemia in blast crisis,” Haematologica, vol. 93, no. 12, pp. 1765–1769, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Baccarani, G. Gugliotta, F. Castagnetti, S. Soverini, and G. Rosti, “European LeukemiaNet recommendations for the management of chronic myeloid leukemia,” Blood, vol. 122, pp. 872–884, 2013. View at Google Scholar
  8. U. Bacher, T. Haferlach, W. Hiddemann, S. Schnittger, W. Kern, and C. Schoch, “Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression,” Cancer Genetics and Cytogenetics, vol. 157, no. 1, pp. 53–61, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. F. E. Nicolini, A. R. Ibrahim, S. Soverini et al., “The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis,” Haematologica, vol. 98, no. 10, pp. 1510–1516, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. V. Grossmann, A. Kohlmann, M. Zenger et al., “A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases,” Leukemia, vol. 25, no. 3, pp. 557–560, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Soverini, A. Hochhaus, F. E. Nicolini et al., “BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of european leukemianet,” Blood, vol. 118, no. 5, pp. 1208–1215, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. A. M. Lewis, W. D. Croughan, N. Aranibar et al., “Understanding and controlling sialylation in a CHO Fc-fusion process,” PLOS ONE, vol. 11, no. 6, p. e0157111, 2016. View at Publisher · View at Google Scholar
  13. Gleevec, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 2012.
  14. Tasigna, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 2012.
  15. Bosulif, Pfizer Labs, New York, NY, USA, 2012.
  16. J. E. Cortes, H. Kantarjian, N. P. Shah et al., “Ponatinib in refractory philadelphia chromosome-positive leukemias,” New England Journal of Medicine, vol. 367, no. 22, pp. 2075–2088, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. M. L. Sorror, M. B. Maris, R. Storb et al., “Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT,” Blood, vol. 106, no. 8, pp. 2912–2919, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Talpaz, N. P. Shah, H. Kantarjian et al., “Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias,” New England Journal of Medicine, vol. 354, no. 24, pp. 2531–2541, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Saglio, A. Hochhaus, Y. T. Goh et al., “Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily,” Cancer, vol. 116, no. 16, pp. 3852–3861, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. T. P. Hughes, G. Saglio, A. Quintás-Cardama et al., “BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase,” Leukemia, vol. 29, no. 9, pp. 1832–1838, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Soverini, C. De Benedittis, K. M. Polakova et al., “Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients,” Oncotarget, vol. 7, no. 16, pp. 21982–21990, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Baer, W. Kern, S. Koch et al., “Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia,” Haematologica, vol. 101, no. 7, pp. 830–838, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. T. O'Hare, M. S. Zabriskie, C. A. Eide et al., “The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia,” Blood, vol. 118, no. 19, pp. 5250–5254, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. F. Cervantes, M. Rozman, J. Rosell, A. Urbano‐Ispizua, E. Montserrat, and C. Rozman, “A study of prognostic factors in blast crisis of Philadelphia chromosome‐positive chronic myelogenous leukaemia,” British Journal of Haematology, vol. 76, no. 1, pp. 27–32, 1990. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Wadhwa, R. M. Szydlo, J. F. Apperley et al., “Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia,” Blood, vol. 99, no. 7, pp. 2304–2309, 2002. View at Publisher · View at Google Scholar · View at Scopus